UCLA Health Study Reveals New Brain Region Involved in Severe Narcolepsy

Los Angeles, May 02: Researchers at UCLA Health have uncovered a significant new insight into the causes of severe narcolepsy, challenging a long-held scientific understanding of the disorder. The findings, published in Nature Communications, reveal that narcolepsy with cataplexy involves degeneration in two regions of the brain—not just one as previously believed.

For nearly 25 years, narcolepsy type 1 has been primarily attributed to the loss of hypocretin-producing neurons in the hypothalamus. However, the new study identifies additional degeneration in the brainstem’s locus coeruleus, a region responsible for producing norepinephrine, a neurotransmitter that regulates wakefulness and muscle tone.

“The locus coeruleus has connections that influence both wakefulness and muscle control, making it a key factor in explaining the dual symptoms of excessive sleepiness and cataplexy,” said Thomas Thannickal, lead author and associate researcher at the David Geffen School of Medicine at UCLA.

Key Findings

The study analyzed postmortem brain tissue from 11 individuals with narcolepsy and five healthy controls. Researchers found:

• A significant loss—averaging 46%—of norepinephrine-producing neurons in the locus coeruleus among narcolepsy patients
• Surviving neurons were approximately 18% larger, suggesting compensatory activity
• Increased neuroinflammation, with more than double the number of immune-related microglial cells
• Evidence that the degeneration is likely immune-mediated rather than a typical neurodegenerative process

Importantly, animal models of narcolepsy did not show similar damage in the locus coeruleus, indicating that this feature may be unique to human disease and not simply a downstream effect of hypocretin loss.

Implications for Diagnosis and Treatment

Narcolepsy affects approximately 1 in 2,000 people and is characterized by excessive daytime sleepiness. In its most severe form, it includes cataplexy—sudden muscle weakness triggered by emotions.

The discovery of a second affected brain region may help explain why 15–30% of patients with narcolepsy symptoms have normal hypocretin levels, a long-standing diagnostic challenge.

“This doesn’t overturn what we know about hypocretin and narcolepsy, but it shows we’ve only been seeing part of the picture,” said Jerome Siegel, senior author and director of the Center for Sleep Research at UCLA. “A more complete understanding of the disease will help us develop more targeted therapies.”

The findings also align with the effectiveness of treatments that enhance norepinephrine activity, suggesting new avenues for therapeutic development.

Advancing Sleep Disorder Research

The study highlights the importance of exploring multiple neurological pathways in complex disorders and underscores the potential role of immune processes in narcolepsy. By expanding the scientific understanding of the condition, the research opens the door to improved diagnostic tools and more personalized treatment strategies.